Such therapies have been associated with complete elimination of testosterone in the tumor microenvironment (such as bone) and in some cases a loss of CYP17 (a key enzyme in androgen biosynthesis) in prostate cancer cells (78–80). Here, CYP17A1 is linked to prostate cancer.